Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Inappropriate Use Of Amfepramone Prompts EU Withdrawal Of Weight-Loss Drug

EMA Issues Warning Over Xalkori And Oular Toxicity In Pediatric Patients

Executive Summary

The European Medicines Agency’s pharmacovigilance committee has recommended removing all amfepramone medicines from the EU market as they continue to be used outside the current risk minimization measures.

You may also be interested in...



The ECJ's Judgment in the Anorectics Case: Effects on Referrals and Variations

Markus Ambrosius examines the implications for pharmaceutical companies of the recent court ruling.

Anorectic Drugs

Court rejects European ban

Misinformation Prompted Six Court Cases Against EU COVID-19 Vaccine Approvals In 2021

The EU’s conditional approval of four COVID-19 vaccines and its decision to extend the use of Pfizer/BioNTech’s Comirnaty to a younger age group were challenged in the court last year but the cases were declared inadmissible.

Topics

Latest News
UsernamePublicRestriction

Register

PS146317

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel